Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024

Press release – No. 5 / 2024

Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024

Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Adam Steensberg, President and CEO, will participate in fireside chats at the following healthcare investor conferences in June:

• Jefferies Global Healthcare Conference, June 4-6 in New York City

Wednesday, June 5 at 10:00 a.m. ET (4:00 p.m. CET)

A webcast of the fireside chat will be available at and accessible through the Events page in the Investor section of Zealand Pharma’s website at where a replay will also be archived after the fireside chat.

• Goldman Sachs 45^th Annual Global Healthcare Conference, June 10-13 in Miami

Wednesday, June 12 at 4:00 p.m. ET (10:00 p.m. CET)

A webcast of the fireside chat will be available at and accessible through the Events page in the Investor section of Zealand Pharma’s website at where a replay will also be archived after the fireside chat.

# # #

About Zealand Pharma

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit .

Contacts: